



Half-Year Report

# 2024 September


**HBM** Healthcare  
Investments

HBM Healthcare Investments invests in the human medicine, biotechnology, medical technology and diagnostics sectors and related areas. The company holds and actively manages an international portfolio of promising companies.

Many of these companies have their lead products already available on the market or at an advanced stage of development. The portfolio companies are closely tracked and actively guided on their strategic directions. This is what makes HBM Healthcare Investments an interesting alternative to investing in big pharma and biotech companies. HBM Healthcare Investments has an international shareholder base and is listed on SIX Swiss Exchange (ticker: HBMN).


**Investments by continents<sup>3)</sup>**

Global portfolio.




**Allocation of assets<sup>1)</sup>**

Mainly invested in private companies or in companies originating from the private companies portfolio.




**Currency allocation of assets<sup>1)</sup>**

Emphasis on US dollar investments.




**Development phase of portfolio companies<sup>3)</sup>**

Mainly invested in revenue generating companies or in companies with products at an advanced stage of development.



**Therapeutic area of the lead product of portfolio companies<sup>3)</sup>**

Broadly diversified areas of activity.



1) Total consolidated assets as at 30.9.2024: CHF 1783 million.  
 2) Net of foreign currency hedge (USD/CHF): About USD 40 percent and CHF 22 percent respectively.  
 3) Total investments as at 30.9.2024: CHF 1603 million.

**Key Figures**


		30.9.2024	31.3.2024	31.3.2023	31.3.2022	31.3.2021
<b>Net assets</b>	CHF million	<b>1 664.3</b>	<b>1 703.9</b>	<b>1 772.7</b>	<b>1 986.5</b>	<b>2 151.5</b>
Investments in private companies and funds		738.3	809.4	846.1	790.3	662.8
Investments in public companies		864.9	768.8	847.0	1 130.2	1 404.2
Cash and cash equivalents (net of liability from market hedging)		119.1	203.4	232.0	223.7	327.0
<b>Net result for the period</b>	CHF million	<b>22.6</b>	<b>-1.1</b>	<b>-146.3</b>	<b>-78.0</b>	<b>756.3</b>
Basic earnings per share	CHF	3.30	-0.16	-21.03	-11.22	108.71
Net asset value (NAV) per share	CHF	244.34	248.10	254.80	285.53	309.25
Share price	CHF	189.40	193.60	214.00	276.00	332.50
<b>Premium (+) / discount (-)</b>	%	<b>-22.5</b>	<b>-22.0</b>	<b>-16.0</b>	<b>-3.3</b>	<b>+7.5</b>
Distribution per share	CHF		7.50	7.50	9.70	12.50 <sup>1)</sup>
Distribution yield	%		3.9	3.5	3.5	3.8
Shares issued	Registered shares (m)	7.0	7.0	7.0	7.0	7.0
Shares outstanding	Registered shares (m)	6.8	6.9	7.0	7.0	7.0

1) Thereof CHF 9.50 as ordinary distribution and CHF 3.00 as a special distribution to mark the 20<sup>th</sup> anniversary of the Company.

**Performance (including distributions)**

		2024/2025 (6 months)	2023/2024	2022/2023	2021/2022	2020/2021
Net asset value (NAV)	%	1.5	0.3	-7.4	-3.6	52.2
Registered share HBMN	%	1.7	-6.0	-18.9	-13.2	79.1

**Indexed performance since launch in CHF (12.7.2001 = 100), distributions reinvested**



HBM Healthcare Investments recorded a profit of CHF 23 million in the first half of the 2024/2025 financial year as of 30 September. Net asset value per share (NAV) increased by 1.5 percent and the share price rose by 1.7 percent. Unfavourable currency movements reduced the Swiss franc performance by almost 5 percent. The partial hedging of the USD currency risk was mitigating this somewhat. Private as well as public companies contributed positively to the overall result. Following two IPOs and a trade sale, the proportion of private companies is just under one third of assets. The portfolio remains broadly diversified. The development of the companies and the creation of value are progressing well in the majority of cases.

#### Dear Shareholders

HBM Healthcare Investments reports a profit of CHF 23 million for the first half of the 2024/2025 financial year. The net asset value per share (NAV) rose by 1.5 percent. The share price rose by 1.7 percent.

Private and public companies contributed to the profit. Negative currency effects reduced performance by just under 5 percent. The partial hedging of the US dollar against the Swiss franc cushioned the currency losses somewhat.

The following investments made the largest contributions to NAV development:

<b>Winners</b>	<b>NAV %</b>	<b>Losers</b>	<b>NAV %</b>
Yellow Jersey Therapeutics (private)	3.5	ConnectRN (private)	-0.8
Swixx BioPharma (private)	1.5	ALX Oncology	-0.7
BioInvent	0.8	Y-mAbs Therapeutics	-0.7
Argenx	0.6	Alumis Therapeutics	-0.4
Insmed	0.6	Pacira BioSciences	-0.4

### Significant developments in the portfolio

The **private companies** recorded a net increase in value of CHF 28 million after deducting currency effects totalling CHF –34 million. In addition to the sale of Yellow Jersey Therapeutics to Johnson & Johnson (profit contribution of CHF 59 million), Swixx BioPharma (CHF 26 million) made a particularly positive contribution to value growth. The company's sales and profits continue to grow, which led to the revaluation of the investment.

The market valuations of Alumis Therapeutics (CHF –6 million) and Fangzhou (CHF –4 million) have fallen slightly following their IPOs. However, both companies still hold strong positions, Alumis with a promising development pipeline of therapies for the treatment of autoimmune diseases and Fangzhou (Jianke) as China's leading online platform for the management of chronic diseases.

Value adjustments were required for ConnectRN (CHF –13 million), Vascular Dynamics (CHF –4 million), eGenesis (CHF –4 million) and Neuron23 (CHF –4 million) due to financing rounds or missed operational targets.

Investments in **funds** recorded a decline in valuation of CHF –17 million, including the currency effect of CHF –10 million.

**Public companies** recorded a net increase in value of CHF 22 million after deducting CHF –45 million due to unfavourable currency developments.

The stock market valuation of Cathay Biotech (profit contribution of CHF 8 million) has recovered from its lows thanks to the economic measures announced by the Chinese government. Moreover, the company has won several new partners and projects for synthetic biology-based materials, which should lead to further sales and profit growth in the coming years. The share price of Harmony Biosciences (CHF 8 million) also recovered thanks to good sales figures for the narcolepsy drug Wakix® and a development pipeline that is attracting increasing attention on the market.

BioInvent (CHF 13 million), Insmad (CHF 10 million), Argenx (CHF 10 million) and ArriVent Biopharma (CHF 5 million) rose on the back of good clinical trial results. The valuation of Pacira BioSciences (CHF –6 million) came under pressure due to the FDA approval of a generic version of the pain drug Exparel®. However, due to ongoing patent proceedings, it remains to be seen whether and how quickly the generic drug will reach the market.

ALX Oncology (CHF –13 million) fell sharply in value following the publication of the results of the phase II ASPEN–06 trial. The combination study with evorpacept for the treatment of advanced HER2-positive gastric cancer showed a significantly improved efficacy compared to a control arm with previous standard therapies. However, at the same time, the drug was less effective than the interim data of a first patient group published in autumn 2023.

**Other assets** made a net contribution to earnings of CHF 2 million.

### **Asset allocation**

In the first six months of the financial year, CHF 40 million was invested in private companies. CHF 6 million of this was attributable to a new investment in Bluejay Therapeutics and CHF 34 million to follow-on financing in private companies and the IPO investment in Alumis (CHF 13 million).

In the portfolio of public companies, new positions were established in Benitec Biopharma, Cartesian Therapeutics and Corbus Pharmaceuticals.

The sale of Yellow Jersey Therapeutics and the IPOs of Fangzhou and Alumis reduced the private companies allocation to 32 percent of assets. By contrast, the share of public companies rose to 49 percent (of which a good half are formerly private companies). 9 percent is accounted for by funds, 7 percent by cash and cash equivalents and 3 percent by other assets.

### **Outlook**

Market sentiment towards the biotechnology sector has improved somewhat in recent months. However, the Federal Reserve's first interest rate cut in September has not yet provided the hoped-for boost to the sector. Uncertainties about the geopolitical situation, further economic development and the upcoming elections in the United States are causing market participants to remain cautious.

Despite this, the development and value creation of our portfolio companies is progressing well. Upstream Bio raised USD 255 million in new capital as part of an IPO at the beginning of October. The funds will be used to further develop the pipeline of therapies for the treatment of allergies and inflammatory diseases. The IPO had a positive effect on the net asset value of the HBM share.

The Indian contract development and manufacturing company SAI Life Sciences is targeting an IPO in Mumbai. The company is profitable and should benefit from the favourable stock market environment in India. This in turn should unlock significant value in our investment.

There are other private companies that have progressed to the point where they are ready to enter into strategic transactions. In addition, several public companies are awaiting market approvals or pivotal trial results. A detailed overview can be found in the investor presentation on our website.

HBM Healthcare Investments' portfolio remains attractive with its mix of emerging private and public companies and is positioned for further value growth.

We would like to thank you, our shareholders, for the trust you have placed in us.



Dr Andreas Wicki  
CEO



Erwin Troxler  
CFO

<b>Balance sheet</b> (CHF 000)	Notes	30.9.2024	31.3.2024
<b>Assets</b>			
<b>Current assets</b>			
Cash and cash equivalents		4743	10227
Receivables		58	60
<b>Total current assets</b>		<b>4801</b>	<b>10287</b>
<b>Non-current assets</b>			
Investment in subsidiary	(3)	1820810	1796281
<b>Total non-current assets</b>		<b>1820810</b>	<b>1796281</b>
<b>Total assets</b>		<b>1825611</b>	<b>1806568</b>
<b>Liabilities</b>			
<b>Current liabilities</b>			
Liability to subsidiary		60000	0
Other liabilities		1851	3314
<b>Total current liabilities</b>		<b>61851</b>	<b>3314</b>
<b>Non-current liabilities</b>			
Financial liabilities	(4)	99480	99389
<b>Total non-current liabilities</b>		<b>99480</b>	<b>99389</b>
<b>Shareholders' equity</b>			
Share capital	(5.1)	32016	84216
Treasury shares	(5.2)	-26927	-15991
Capital reserve		143248	142250
Retained earnings		1515943	1493390
<b>Total shareholders' equity</b>		<b>1664280</b>	<b>1703865</b>
<b>Total liabilities and shareholders' equity</b>		<b>1825611</b>	<b>1806568</b>
Number of outstanding shares (in 000)		6811	6868
Net asset value (NAV) per share (CHF)		244.34	248.10



<b>Statement of comprehensive income for the period 1 April to 30 September (CHF 000)</b>	Notes	Quarter ended 30.9.2024	Quarter ended 30.9.2023	6-month period ended 30.9.2024	6-month period ended 30.9.2023
Net change in value of investment in subsidiary	(3)	-1 908	-58 395	24 529	-68 081
<b>Result from investment activities</b>		<b>-1 908</b>	<b>-58 395</b>	<b>24 529</b>	<b>-68 081</b>
Personnel expenses	(6)	-392	-399	-782	-809
Other operating expenses		-347	-291	-570	-446
<b>Result before interest and taxes</b>		<b>-2 647</b>	<b>-59 085</b>	<b>23 177</b>	<b>-69 336</b>
Financial expenses		-338	-382	-670	-1 043
Financial income		37	65	46	70
<b>Net result for the period</b>		<b>-2 948</b>	<b>-59 402</b>	<b>22 553</b>	<b>-70 309</b>
<b>Comprehensive result</b>		<b>-2 948</b>	<b>-59 402</b>	<b>22 553</b>	<b>-70 309</b>
Number of outstanding shares, time-weighted (in 000)		6 823	6 954	6 837	6 955
Basic earnings per share (CHF)		-0.43	-8.54	3.30	-10.11

As the Company does not have options or similar instruments outstanding, diluted earnings per share are identical to basic earnings per share.

<b>Statement of cash flows for the period 1 April to 30 September (CHF 000)</b>	6-month period ended 30.9.2024	6-month period ended 30.9.2023
Expenses paid (personnel and other operating expenses)	- 1 624	- 969
<b>Net cash flow from operating activities</b>	<b>- 1 624</b>	<b>- 969</b>
Interest received / paid	- 1 096	- 2 326
Redemption of financial liabilities	0	- 50 000
Loan from subsidiary	60 000	105 000
Par value repayment	- 51 202	- 52 151
Purchase of treasury shares	- 11 562	- 733
<b>Net cash flow from financing activities</b>	<b>- 3 860</b>	<b>- 210</b>
<b>Currency translation differences</b>	<b>0</b>	<b>0</b>
<b>Net change in cash and cash equivalents</b>	<b>- 5 484</b>	<b>- 1 179</b>
Cash and cash equivalents at beginning of period	10 227	5 732
Cash and cash equivalents at end of period	4 743	4 553

<b>Statement of changes in equity (CHF 000)</b>	Share capital	Treasury shares	Capital reserve	Retained earnings	Total shareholders' equity
<b>Balance 31 March 2023</b>	<b>136 416</b>	<b>- 402</b>	<b>142 201</b>	<b>1 494 473</b>	<b>1 772 688</b>
Comprehensive result				- 70 309	- 70 309
Purchase of treasury shares		- 733			- 733
Par value repayment (7.8.2023)	- 52 200		49		- 52 151
<b>Balance 30 September 2023</b>	<b>84 216</b>	<b>- 1 135</b>	<b>142 250</b>	<b>1 424 164</b>	<b>1 649 495</b>
Comprehensive result				69 226	69 226
Purchase of treasury shares		- 14 856			- 14 856
<b>Balance 31 March 2024</b>	<b>84 216</b>	<b>- 15 991</b>	<b>142 250</b>	<b>1 493 390</b>	<b>1 703 865</b>
Comprehensive result				22 553	22 553
Purchase of treasury shares		- 10 936			- 10 936
Par value repayment (9.8.2024)	- 52 200		998		- 51 202
<b>Balance 30 September 2024</b>	<b>32 016</b>	<b>- 26 927</b>	<b>143 248</b>	<b>1 515 943</b>	<b>1 664 280</b>

## General Statements

### 1. Information about the Company and its business

HBM Healthcare Investments Ltd (HBM Healthcare or Company) is a SIX Swiss Exchange-listed holding company domiciled at Bundesplatz 1, Zug (Switzerland). The purpose of the Company is the acquisition, holding and sale of positions in other companies as well as the management and financing of such positions in the human medicine, biotechnology, medical technology and diagnostics sectors, and related areas.

### 2. Accounting policies

The condensed interim financial statements have been prepared in accordance with the IFRS Accounting Standards IAS 34 on Interim Financial Reporting, and the provisions of the SIX Swiss Exchange Additional Rules on the Listing of Investment Companies. These interim financial statements should be read in conjunction with the Group Financial Statements for the financial year ended 31 March 2024, as they provide an update to the latest full financial report.

In preparing the interim financial statements, the same accounting policies and methods of computation have been applied as in the preparation of the annual financial statements as at 31 March 2024. The Group Financial Statements comprise HBM Healthcare Investments Ltd and the non-consolidated investment in the HBM Healthcare Investments (Cayman) Ltd. subsidiary (Subsidiary). A summary of the newly applied IFRS/IAS standards and interpretations in the reporting period is provided on pages 69 and 70 of the Group Financial Statements of the 2023/2024 Annual Report.

The newly applied standards and interpretations had no material impact on the Group's accounting policies, overall results or financial position.

Unless indicated otherwise, the values are in thousands of CHF.

The following exchange rates were used in the preparation of the financial statements:

Exchange rates (CHF)	30.9.2024	31.3.2024
CAD	0.6252	0.6657
CNY	0.1205	0.1248
DKK	0.1263	0.1304
EUR	0.9416	0.9726
GBP	1.1310	1.1378
HKD	0.1088	0.1152
INR	0.0101	0.0108
SEK	0.0832	0.0846
USD	0.8456	0.9014

## Notes to the Balance Sheet and Statement of Income

### 3. Investment in Subsidiary

The fair value of the investment in the Subsidiary HBM Healthcare Investments (Cayman) Ltd. developed as follows during the 6-month period:

<b>Development fair value investment</b> (CHF 000)	6-month period ended 30.9.2024	6-month period ended 30.9.2023
<b>Fair value at beginning of period</b>	<b>1 796 281</b>	<b>1 918 299</b>
Change in value, gross	24 529	-68 081
<b>Fair value at end of period</b>	<b>1 820 810</b>	<b>1 850 218</b>

Net assets of the investment in the Subsidiary comprised the following as at the balance sheet date:

<b>Composition net assets</b> (CHF 000)	Notes	30.9.2024	31.3.2024	30.9.2023
Cash and cash equivalents		114 382	193 187	82 323
Receivables		74	29	84
Loan to parent company		60 000	0	105 000
Investments	(3.1)			
Private companies		576 752	635 252	682 725
Funds		161 510	174 146	173 363
Public companies		864 860	768 763	787 802
Shares of parent company		11 600	10 675	11 922
Financial instruments	(3.2)	20 802	1 836	1 872
Other financial assets	(3.3)	28 323	29 055	30 314
<b>Total assets</b>		<b>1 838 303</b>	<b>1 812 943</b>	<b>1 875 405</b>
Provision for deferred tax on capital gain and other taxes	(3.5)	-17 162	-16 267	-24 944
Other current liabilities		-331	-395	-243
<b>Total net assets at fair value</b>		<b>1 820 810</b>	<b>1 796 281</b>	<b>1 850 218</b>

During the 6-month period, the net assets of the investment in the Subsidiary have developed as follows:

<b>Change in net assets at fair value</b> (CHF 000)	Notes	6-month period ended 30.9.2024	6-month period ended 30.9.2023
Net result on investments	(3.1)	32 708	–73 497
Change in provision for deferred tax on capital gain and other taxes		–895	4 186
Dividend income		1 269	1 319
Net result from financial instruments	(3.2)	15 994	1 661
Net result from other financial assets		–15 035	10 187
Net result from shares of parent company		248	–1 587
<b>Result from investing activities</b>		<b>34 289</b>	<b>–57 731</b>
Management fee	(3.4)	–11 544	–12 052
Personnel and other operating expenses		–523	–528
Financial result		2 307	2 230
<b>Change in value, gross</b>		<b>24 529</b>	<b>–68 081</b>
<b>Net change in value of investment</b>		<b>24 529</b>	<b>–68 081</b>

For details of individual items of net assets (balance and change), please refer to the following explanations.

### 3.1 Investments

During the 6-month period, the investments held by the Subsidiary comprised the following and they performed as follows:

<b>Development of investments</b> (CHF 000)	Private companies	Funds	Public companies	Total investments
<b>Fair value 31 March 2024</b>	<b>635 252</b>	<b>174 146</b>	<b>768 763</b>	<b>1 578 161</b>
Reclassification owing to IPO (Alumis Therapeutics)	–2 253		2 253	0
Reclassification owing to IPO (Fangzhou Jianke)	–41 955		41 955	0
<b>Fair value 31 March 2024 (after reclassification)</b>	<b>591 044</b>	<b>174 146</b>	<b>812 971</b>	<b>1 578 161</b>
Purchases	35 434	7 095	99 176	141 705
Sales	–81 244	–2 345	–65 863	–149 452
Realised gains	59 191	70	12 377	71 638
Realised losses	–7	–236	–10 194	–10 437
Changes in unrealised gains/losses	–27 666	–17 220	16 393	–28 493
Net result on investments	31 518	–17 386	18 576	32 708
<b>Fair value 30 September 2024</b>	<b>576 752</b>	<b>161 510</b>	<b>864 860</b>	<b>1 603 122</b>

Details on investments can be found on pages 14 to 16.

Private companies	Domicile	Investment currency	Amount disbursed 31.3.2024	Changes in reporting period	Amount disbursed 30.9.2024	Fair value 30.9.2024	Ownership 30.9.2024	Fair value 30.9.2024	Fair value 31.3.2024
			IC million	IC million	IC million	IC million	%	CHF 000	CHF 000
Swixx BioPharma	CH	EUR	34.8		34.8	212.9	25.1	200 459	174 920
Neurelis	US	USD	24.4		24.4	56.2	10.3	47 545	50 682
Upstream Bio	US	USD	22.5	7.5	30.0	44.0	6.4	37 206	32 901
NiKang Therapeutics	US	USD	20.0		20.0	25.2	5.3	21 349	22 757
ConnectRN	US	USD	19.9	4.0	23.9	23.0	20.0	19 461	28 871
Dren Bio	US	USD	15.0		15.0	22.7	8.1	19 213	20 481
Tata 1mg	IN	INR	1 130.1		1 130.1	1 791.7	4.0	18 079	19 364
Nuance Biotech	CN	USD	14.0		14.0	18.7	3.7	15 789	16 831
Valo Health	US	USD	17.5		17.5	17.5	1.4	14 798	15 774
SAI Life Sciences	IN	INR	449.0		449.0	1 343.9	5.4	13 561	14 525
River Renal	US	USD	14.0	2.0	16.0	16.0	14.0	13 530	12 620
Odyssey Therapeutics	US	USD	14.3		14.3	15.3	2.6	12 913	13 765
Cure Everlife Holdings	MU	USD	7.3		7.3	14.1	6.8	11 964	12 754
Shape Memory Medical	US	USD	11.8		11.8	14.0	16.7	11 816	12 596
Numab / Yellow Jersey Therapeutics <sup>1)</sup>	CH	CHF	22.1	-11.0	11.1	11.1	7.8	11 063	22 127
Fore Biotherapeutics	US	USD	14.5	2.1	16.6	12.9	9.0	10 942	9 763
Aculys Pharma	JP	USD	6.0		6.0	9.9	4.8	8 377	8 929
Genalyte (BaseHealth)	US	USD	8.8		8.8	9.7	3.6	8 202	8 743
C-Ray Therapeutics	CN	USD	9.0		9.0	9.0	4.0	7 645	8 150
Mahzi Therapeutics	US	USD	8.0	0.5	8.5	8.5	9.7	7 158	7 211
Ignis Therapeutics	CN	USD	7.0		7.0	7.0	1.5	5 919	6 310
Arrakis Therapeutics	US	USD	7.0		7.0	7.0	4.6	5 919	6 310
Bluejay Therapeutics	US	USD	0.0	7.0	7.0	7.0	1.8	5 919	0
Karius	US	USD	17.7		17.7	6.7	4.0	5 633	6 005
FogPharma	US	USD	9.4		9.4	5.7	1.4	4 805	5 122
Farmalatam	PA	USD	30.6		30.6	4.8	42.6	4 017	4 282
1000Farmacie	IT	EUR	5.5		5.5	4.0	14.5	3 793	3 918
Neuron23	US	USD	8.0		8.0	4.3	2.2	3 659	7 314
ADARx Pharmaceuticals	US	USD	4.0		4.0	4.0	0.5	3 382	3 606
Others								22 633	34 414
<b>Total private companies</b>								<b>576 752</b>	<b>591 045</b>

1) Yellow Jersey Therapeutics had been demerged from Numab Therapeutics and was acquired. The transaction was completed during the reporting period. HBM continues to hold a stake in Numab Therapeutics.

Funds	Invest- ment currency	Total commitment	Payments in reporting period	Repayments in reporting period	Cumulative payments 30.9.2024	Cumulative repayments 30.9.2024	Fair value 30.9.2024	Fair value 30.9.2024	Fair value 31.3.2024
	IC	IC million	IC million	IC million	IC million	IC million	IC million	CHF 000	CHF 000
HBM Genomics	USD	25.3			25.3	3.5	43.0	36 330	41 426
120 Capital	USD	25.0	2.5		25.0	0.0	24.7	20 866	20 159
MedFocus Fund II	USD	26.0			26.0	25.0	22.2	18 807	20 097
Tata Capital Healthcare Fund II	USD	20.0	3.4	0.7	19.4	2.3	17.0	14 337	12 909
C-Bridge Healthcare Fund V	USD	15.0	0.8	0.5	12.9	1.3	15.4	13 004	13 633
C-Bridge Healthcare Fund IV	USD	10.0	0.1		10.2	0.2	15.3	12 909	13 725
6 Dimensions Capital	USD	25.0			25.0	32.3	11.3	9 569	11 646
HBM Genomics II	USD	15.0			10.8	0.0	10.4	8 830	8 844
WuXi Healthcare Ventures II	USD	20.0			20.0	6.4	10.2	8 623	11 387
LYZZ Capital Fund II	USD	15.0	1.0		8.4	0.0	7.9	6 668	6 329
Tata Capital HBM Fund I	USD	10.0		0.7	9.9	7.6	5.6	4 705	5 805
Others								6 862	8 186
<b>Total funds</b>								<b>161 510</b>	<b>174 146</b>

Public companies	Invest- ment currency	Balance 31.3.2024	Changes 6 months	Changes 3 months	Balance 30.9.2024	Share price 30.9.2024	Ownership 30.9.2024	Fair value 30.9.2024	Fair value 31.3.2024
	IC	Number of shares	Number of shares	Number of shares	Number of shares	IC	%	CHF 000	CHF 000
<b>Companies originating from private companies' portfolio</b>									
Cathay Biotech <sup>1)</sup>	CNY	35 621 436	0	0	35 621 436	47.54	6.1	204 023	196 236
Harmony Biosciences	USD	2 147 943	0	0	2 147 943	40.00	3.8	72 652	65 016
Fangzhou (Jianke) <sup>2)</sup>	HKD	58 420 980	0	0	58 420 980	7.09	4.4	45 060	41 955
Y-mAbs Therapeutics	USD	3 297 800	0	0	3 297 800	13.15	7.4	36 670	48 335
ArriVent Biopharma	USD	1 126 385	218 074	0	1 344 459	23.50	4.0	26 717	18 134
Mineralys Therapeutics	USD	2 246 332	0	0	2 246 332	12.11	4.5	23 003	26 141
Alumis Therapeutics <sup>2)</sup>	USD	170 399	1 107 899	0	1 278 298	10.68	2.7	11 544	2 253
Monte Rosa Therapeutics	USD	1 407 040	0	0	1 407 040	5.30	2.3	6 306	8 942
Pacira BioSciences	USD	451 324	0	0	451 324	15.05	1.0	5 744	11 887
Others								12 103	30 306
<b>Total companies originating from private companies' portfolio</b>								<b>443 822</b>	<b>449 205</b>
<b>Various companies</b>									
Biohaven	USD	576 280	317 099	0	893 379	49.97	0.9	37 749	28 409
Merus	USD	748 203	106 996	0	855 199	49.96	1.3	36 129	30 370
Aurobindo Pharma	INR	1 604 630	0	0	1 604 630	1 460.70	0.3	23 651	18 881
Argenx (ADR)	USD	50 000	0	0	50 000	542.08	0.1	22 919	17 745
Argenx	EUR	50 000	0	0	50 000	485.60	0.1	22 861	17 804
Natera	USD	200 000	0	0	200 000	126.95	0.2	21 470	16 488
Biolnvent	SEK	5 075 000	0	0	5 075 000	48.25	7.7	20 379	7 296
Zymeworks	USD	1 519 259	177 958	0	1 697 217	12.55	2.4	18 011	14 407
Traverse Therapeutics	USD	1 500 000	0	0	1 500 000	13.99	2.0	17 745	10 425
Axsome Therapeutics	USD	166 053	0	0	166 053	89.87	0.4	12 619	11 944

Continued as well as footnotes on page 16

Public companies	Investment currency	Balance 31.3.2024	Changes 6 months	Changes 3 months	Balance 30.9.2024	Share price 30.9.2024	Ownership 30.9.2024	Fair value 30.9.2024	Fair value 31.3.2024
	IC	Number of shares	Number of shares	Number of shares	Number of shares	IC	%	CHF 000	CHF 000
<b>Various companies</b>									
Beigene	HKD	700 000	0	0	700 000	144.70	0.1	11 019	7 669
Beigene (ADR)	USD	50 000	0	0	50 000	224.51	0.1	9 492	7 048
Laurus Labs	INR	2 304 700	0	0	2 304 700	463.60	0.4	10 781	9 773
Rocket Pharmaceuticals	USD	625 000	51 320	0	676 320	18.47	0.7	10 563	15 177
Jubilant Pharmova	INR	835 522	35 894	35 894	871 416	1 150.80	0.6	10 119	5 146
Dishman Carbogen	INR	5 560 116	0	0	5 560 116	180.08	3.6	10 103	14 154
Polypeptide	CHF	300 000	0	0	300 000	30.50	0.9	9 150	9 090
Hutchmed China	HKD	2 575 000	0	0	2 575 000	32.20	0.3	9 020	7 935
Shenzhen Mindray	CNY	240 000	0	0	240 000	293.00	<0.1	8 472	8 431
Insmed	USD	278 028	-144 028	-144 028	134 000	73.00	0.1	8 272	6 799
Kura Oncology	USD	500 000	0	0	500 000	19.54	0.7	8 262	9 613
Abivax	EUR	700 000	0	0	700 000	10.16	1.1	6 696	9 123
Benitec Biopharma	USD	0	841 395	0	841 395	9.19	8.0	6 539	0
Solara Active Pharma Sciences	INR	784 958	0	0	784 958	787.90	2.2	6 241	3 147
Vicore Pharma	SEK	10 874 727	-740 123	0	10 134 604	7.21	9.1	6 081	13 501
Cartesian Therapeutics	USD	0	412 364	197 130	412 364	16.12	1.7	5 621	0
Corbus Pharmaceuticals	USD	0	320 000	320 000	320 000	20.63	2.7	5 582	0
Others								45 492	63 390
<b>Total various companies</b>								<b>421 038</b>	<b>363 765</b>
<b>Total public companies</b>								<b>864 860</b>	<b>812 970</b>
<b>Total investments</b>								<b>1 603 122</b>	<b>1 578 161</b>

1) The tax on capital gain and other taxes owed on the sale of the investment in China are accrued separately (note 3.5).

2) The company went public during the reporting period. The investment was listed under private companies in previous reports.



### 3.2 Financial instruments

The Subsidiary buys and sells derivative financial instruments in the course of its ordinary business

activities and as part of its risk management. The following positions were held as at the balance sheet date:

<b>Holdings of financial instruments (CHF 000)</b>	<b>30.9.2024</b>	<b>31.3.2024</b>
<b>Currency hedging</b>		
Forward contracts for currency hedging purposes	13 818	0
<b>Other financial instruments</b>		
Purchased call and put options	6 984	1 836
<b>Total financial instruments long</b>	<b>20 802</b>	<b>1 836</b>

As at the balance sheet date, the foreign currency risk derived from the USD/CHF exchange rate was partially hedged by means of a forward sale of USD 0.4 billion. The market value of the hedging position amounted to CHF 13.8 million as at the balance sheet date.

The following gains and losses resulted from derivatives transactions conducted during the 6-month period:

<b>Income from financial instruments (CHF 000)</b>	<b>6-month period ended 30.9.2024</b>	<b>6-month period ended 30.9.2023</b>
Gains from currency hedging transactions	13 818	0
Gains from other financial instruments	2 838	1 687
<b>Total gains from financial instruments</b>	<b>16 656</b>	<b>1 687</b>
Losses from other financial instruments	- 662	- 26
<b>Total losses from financial instruments</b>	<b>- 662</b>	<b>- 26</b>
<b>Net result from financial instruments</b>	<b>15 994</b>	<b>1 661</b>

### 3.3 Other financial assets

Other financial assets consist primarily of contractual claims to purchase price payments from earlier trade sales that are contingent on the achievement of defined targets (milestone payments). These claims are recognised at fair value through profit and loss by applying a probability-weighted valuation approach based on the assessment of the likelihood of attaining the underlying targets. These claims are discounted over time at a discount rate of 11.0 percent (previous year: 11.0 percent). The valuation

measures applied refer to commonly used industry statistics as well as own guidelines and estimates.

The total book value as at 30 September 2024, CHF 28.3 million, was carried as other financial assets.

If the companies concerned are successful, these contractual claims could result in future payments which are many times the reported book value.

The following summary shows the value carried in the balance sheet compared with the potential cash flows:

<b>Balance sheet value and potential cash flows</b> (CHF million)	<b>Book value</b> 30.9.2024	<b>Cash flows</b> minimum	<b>Cash flows</b> maximum	<b>Expected period</b> of payment
Surface Logix <sup>1)</sup>	10.8	0.0	14.6	2024 – 2030
Numab / Yellow Jersey Therapeutics	7.1	0.0	8.7	2025
Corvidia Therapeutics	5.7	0.0	37.2	2026 – 2029
Vitaeris	3.8	0.0	75.5	2027 – 2031
Forbius (Formation Biologics)	0.4	0.4	0.4	2024
Alydia Health	0.3	0.0	1.4	2024 – 2026
Tandem Life (Cardiac Assist)	0.2	0.2	0.2	2024
<b>Total</b>	<b>28.3</b>	<b>0.6</b>	<b>138.0</b>	

1) The valuation is based on a previous sale of license rights, formerly owned by Surface Logix, to Kadmon Pharmaceuticals, which was acquired by Sanofi. HBM Healthcare is entitled to receive royalty payments on sales.

### 3.4 Management fee and performance fee

The management fee due to HBM Partners amounts to 0.75 percent per year of the Company's assets plus 0.75 percent per year of its market capitalisation, payable quarterly at the beginning of a quarter. In the 6-month period, HBM Partners was paid CHF 11.5 million (previous year: CHF 12.1 million).

No provision for a performance fee was made during the 6-month period (previous year: none) because net assets as at the balance sheet date did not exceed the highest net assets (high water mark) used as the calculation basis for the last performance fee payment.

The high water mark for all outstanding shares is CHF 290.57 (adjusted for any dividends and capital repayments to shareholders). The cut-off date for the payment of any performance fee is 31 March of a financial year.

### 3.5 Provision for deferred tax on capital gain and other taxes

Provisions in the amount of CHF 17.2 million (as at 31 March 2024: CHF 16.3 million) are recognised for any tax on capital gain and other taxes owed in China that arise on the sale of the investment in Cathay Biotech. The tax on capital gain is calculated on the difference between the relevant tax base and the disclosed fair value or the price realised on the sale of shares up to the reporting date, respectively. In addition, a sales tax may arise, which is calculated on the difference between the potential selling price and the issue price of the shares at the IPO.

### 3.6 Off-balance-sheet commitments

The Subsidiary had the following investment commitments as at the balance sheet date:

<b>Investment commitments</b> (CHF 000)	<b>30.9.2024</b>	<b>31.3.2024</b>
Funds	11 512	19 524
Private companies	3 463	16 383
Public companies	644	0
<b>Total investment commitments</b>	<b>15 619</b>	<b>35 907</b>

#### 4. Financial liabilities

The following financial liability was outstanding as at the balance sheet date: one straight bond listed on SIX Swiss Exchange with a par value of CHF 100 million, coupon of 1.125 percent and maturing on 12 July 2027; to be redeemed at 100 percent of par value.

The bond could become due for early repayment, if the outstanding investment commitments to investment funds exceed the amount of CHF 200 million, or the fair value of all investments in public portfolio companies plus cash and cash equivalents is less than two and a half times the amount of the interest-bearing financial liabilities.

The straight bond is carried at amortised cost, subject to the effective interest method. The difference between the net proceeds and the amount repayable when the bond falls due for redemption is amortised over the term of the bond and charged to financial expenses along with the interest that has been paid. The effective interest rate applied is 1.32 percent.

The fair value of the straight bond amounts to CHF 99.3 million (as at 31 March 2024: CHF 97.7 million) with a carrying amount of CHF 99.5 million (as at 31 March 2024: CHF 99.4 million). The bond is recognised under non-current liabilities.

#### 5. Shareholders' equity

##### 5.1 Share capital and capital reserve

As at the balance sheet date, the Company's share capital stood at CHF 32.02 million, divided into 6960000 registered shares at a par value of CHF 4.60 each.

The Shareholders' Meeting of 17 June 2024 approved a cash distribution of CHF 7.50 per share by means of a withholding tax exempt par value repayment. The cash payment was made on 9 August 2024 after the expiration of the legal deadlines.

##### 5.2 Treasury shares

The Shareholders' Meeting of 10 June 2022 authorised the Board of Directors to repurchase a maximum of 696000 of the Company's own shares via a second trading line. The aim of this share buy-back programme is to cancel the shares as part of a capital reduction. It will be completed no later than 27 June 2025 ("2022 share buy-back programme").

The Company holds 148620 of its own shares (as at 31 March 2024: 92270) as at the balance sheet date. In the 6-month period, 56350 of the Company's own shares were acquired at an average price of CHF 194.08 (previous year: 3660 at CHF 200.54).

##### Holdings from second trading line (number of own shares)

<b>Beginning of period 1 April 2024</b>	<b>92270</b>
Acquired via second trading line under share buy-back programme	56350
<b>End of period 30 September 2024</b>	<b>148620</b>

In addition, the subsidiary HBM Healthcare Investments (Cayman) Ltd. holds 61244 treasury shares (as at 31 March 2024: 55139), acquired via the regular trading line. During the 6-month period, the Subsidiary acquired a total of 39918 treasury shares via the regular trading line at an average price of CHF 191.29 per share (previous year: 53452 at CHF 197.08) and sold 33813 treasury shares at an average price of CHF 191.02 (previous year: 22219 at CHF 199.46).

**hbmhealthcare.com**  
Company website

**CH 0012627250**  
ISIN

**HBMN**

SIX Swiss Exchange Ticker

#### Significant shareholders

Based on the notifications received by the Company, the following shareholders reported equity holdings in HBM Healthcare Investments Ltd of three percent or more as at 30 September 2024:

#### Shareholding

15–20% Nogra Pharma Invest S.à.r.l., Luxembourg /  
Nogra Two S.à.r.l., Luxembourg

#### Fees

Management fee (paid quarterly):  
0.75% of Company assets plus  
0.75% of the Company's market capitalisation  
Performance fee (paid annually):  
15% on increase in value above the high water mark  
High water mark (per share for all outstanding  
shares) for financial year 2024/2025:  
NAV of CHF 290.57

#### Board of Directors and Management

Hans Peter Hasler, Chairman

Mario G. Giuliani, Member

Dr Elaine V. Jones, Member

Dr Rudolf Lanz, Member

Dr Stella X. Xu, Member

Dr Benedikt Suter, Secretary

Dr Andreas Wicki, Chief Executive Officer

Erwin Troxler, Chief Financial Officer

#### Investment Advisor

HBM Partners Ltd, Zug [www.hbmpartners.com](http://www.hbmpartners.com)

**Credits**

Editorial

HBM Healthcare Investments Ltd

Concept and realisation

Weber-Thedy Strategic Communication

Design

Küng Art Direction

Layout and print

DAZ

Copyright

© 2024 HBM Healthcare Investments Ltd

Interim reports are published in English and German.

The German version is binding in all matters of interpretation.



HBM Healthcare Investments Ltd  
Bundesplatz 1, 6300 Zug/Switzerland  
Phone +41 41 710 75 77  
[www.hbmhealthcare.com](http://www.hbmhealthcare.com)